A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients With Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
Latest Information Update: 02 Aug 2022
At a glance
- Drugs SAR 445419 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2022 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
- 27 Jul 2022 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 27 Jul 2022 Planned initiation date changed from 1 Dec 2021 to 1 May 2023.